Prolight Diagnostics announces today that they have received a Notice of Intention to Grant from the European Patent Office (EPO) for patent protection of their single molecule counting POC technology. This is the first application that will be granted in any territory for the Psyros™ technology.
This application (EP 3987287) protects the fundamental measurement system used in the Psyros™ high sensitivity assay platform. The system uses photoactive reporter molecules to permanently bleach dark spots in a fluorescent layer, with each spot representing a single binding event. A number of formalities will now take place before the process is complete and the patent is fully granted by the EPO.
“We are delighted that the EPO intends to grant our first patent application. This validates the novelty and inventiveness of the Psyros technology and should pave the way for worldwide protection in other territories,” said Steve Ross, CTO at Prolight Diagnostics.
“This approval will strengthen Prolight’s intellectual property protection and reinforce the company´s technological leadership in point-of-care. It’s a true milestone in the development of our first launch product, a point-of-care test for high sensitive troponin,” said Ulf Bladin, CEO of Prolight Diagnostics.
Prolight currently have six families of patent applications relating to the Psyros™ technology. The first three are currently in the national / regional phases in a range of territories worldwide. Families four and five are in the PCT phase and will enter the national / regional phases later this year. The sixth is a priority application in the UK.
